Immunotherapy shows promise in treating advanced MCC, surpassing the efficacy of previous treatments; however, a significant portion of advanced MCC cases do not respond to PD‐1/PD‐L1 inhibitors. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.